Mylan on go with generic Malarone

Mylan (MYL) launches its generic version of Glaxo's (GSK) Malarone Tablets (atovaquone & proguanil hydrochloride 62.5 mg/25 mg and 250 mg/100 mg) for the prophylaxis and treatment of P. falciparum malaria. According to IMS Health, Malarone generated ~$89M in U.S. sales for the 12-month period ending March 31, 2014.

Mylan has 299 other ANDAs pending FDA approval.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs